FibroGen, Inc. To Report Second Quarter 2015 Financial Results On August 13, 2015
SAN FRANCISCO, Aug. 10, 2015 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs, today announced that it will report second quarter 2015 financial results on Thursday, August 13, 2015 after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT).
Audio Webcast
Interested parties may access a live audio webcast of the conference call via the investor section of the FibroGen website, www.fibrogen.com. It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software. A replay of the webcast will be available shortly after the call for a period of four weeks.
Dial In Information
| Live (U.S. / Canada): (800) 708-4540 |
| Live (International): (847) 619-6397 |
| Confirmation number: 40444300 |
About FibroGen
FibroGen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The company utilizes its extensive experience in fibrosis and hypoxia-inducible factor (HIF) biology to generate development programs in multiple therapeutic areas. Its most advanced product candidate, roxadustat, or FG-4592, is an oral small molecule inhibitor of HIF prolyl hydroxylases, or HIF-PHs, in Phase 3 clinical development for the treatment of anemia in CKD. A second product candidate, FG-3019, is a monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer. For more information please visit: www.fibrogen.com.
CONTACT: Greg Mann FibroGen, Inc. 415-978-1433 gmann@fibrogen.com
Help employers find you! Check out all the jobs and post your resume.